Vivos Therapeutics (Vivos Therapeutics) Debt-to-Asset : 0.16 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics Debt-to-Asset?

Vivos Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.48 Mil. Vivos Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.40 Mil. Vivos Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $11.80 Mil. Vivos Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 0.16.

Vivos Therapeutics Debt-to-Asset Historical Data

The historical data trend for Vivos Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics Debt-to-Asset Chart

Vivos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.49

0.05

0.18

0.19

Vivos Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.14	0.16	0.20	0.19	0.16

Competitive Comparison of Vivos Therapeutics's Debt-to-Asset

For the Medical Devices subindustry, Vivos Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivos Therapeutics's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Vivos Therapeutics's Debt-to-Asset falls into.

Vivos Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Vivos Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.474	+	1.521)	/	10.73
	=	0.19

Vivos Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.483	+	1.399)	/	11.804
	=	0.16

Vivos Therapeutics (NAS:VVOS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Vivos Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Therapeutics (Vivos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120

Website

https://www.vivos.com

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.

Executives

Ronald Kirk Huntsman	director, 10 percent owner, officer: Chairman & CEO	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman	officer: Chief Financial Officer	6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow	director	REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson	director	2 MUSICK, IRVINE CA 92618
Anja B Krammer	director	C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh	director, 10 percent owner, officer: Chief Medical Officer	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129